Protara Therapeutics announced promising results from its Phase 2 ADVANCED-2 trial for TARA-002, an investigational therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study shows a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback